Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Melis M, Tang X-, Attarwala N, Chen Q, Prishker C, Qin L, et al. A retinoic acid receptor β2 agonist protects against alcohol liver disease and modulates hepatic expression of canonical retinoid metabolism genes. Biofactors. 2022;48(2):469-480.

Marchionni L, Lobo FP, Kostadinov R, Serra A, Besso FG, Deaglio S, et al. Donor-derived acute myeloid leukemia in solid organ transplantation. Am J Transplant. 2022;22(12):3111-3119.

Szczepanski JM, Hissong E, Manthei DM. Use of Selective Arterial Calcium Stimulation Testing in Identification of Insulinoma in a Patient After Bariatric Surgery. Lab Med. 2022;53(2):e40-e43.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.

Man L, Guahmich NL, Kallinos E, Caiazza B, Khan M, Liu Z-, et al. Chronic superphysiologic AMH promotes premature luteinization of antral follicles in human ovarian xenografts. Sci Adv. 2022;8(10):eabi7315.

Charpentier M, Spada S, Van Nest SJ, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol. 2022;86(Pt 2):737-747.

Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2022;21(10):103158.

Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, et al. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022;40(35):4119-4128.

Panarelli NC. In Reply. Arch Pathol Lab Med. 2022;146(10):1182a-1182.

Cai PY, Asad M, Augello MA, Martin L, Louie C, Basourakos SP, et al. A multidisciplinary approach to optimize primary prostate cancer biobanking. Urol Oncol. 2022;40(6):271.e1-271.e7.